摘要
Avastin与血管内皮生长因子(VEGF)结合并阻断其生物活性,从而抑制新生血管的生成,目前已逐渐应用于各种眼部新生血管性及渗出性疾病的治疗,并取得了显著疗效。基于VEGF及其受体在体内正常组织广泛表达,并在血管发育、神经保护及其他正常生理活动中起重要作用,干扰这一途径,如特异性或过度抗VEGF治疗将导致正常生理功能的缺失,继而诱导产生不良反应。因而,通过体内外基础实验及临床应用研究其用药安全性至关重要,目前已受到眼科医师及学者的广泛关注。
Bevacizumab（Avastin）is a full-length humanized murine monoclonal antibody combined with VEGF molecule against its function,so as to inhibit neovascularization.Now it is not only widely available in treatment of neoplasms but also has obtained significant effects in new-vascular ophthalmopathy.Meanwhile,the safety of using Avastin is a concern among ophthalmologists around the Globe.VEGF is not only an important angiogenic factor,but is also important for the proliferation of neuronal precursors,development and survival of a variety of neurons in the central nervous system,including the retina,where it is expressed by neurones and the Müller cells.Therefore,it is of great interest to make sure that depletion of VEGF does not affect survival and normal function of retinal neurons and other normal tissues.This article reviewed the safety of Avastin in basis and ophthalmological application.
出处
《医学综述》
2010年第10期1551-1553,共3页
Medical Recapitulate
关键词
贝伐单抗
血管内皮生长因子
玻璃体腔注药
Bevacizumab
Vascular endothelial growth factor
Intravitreal injections
